Business Wire

QUECTEL-WIRELESS

9.4.2024 09:01:27 CEST | Business Wire | Press release

Share
Quectel Broadens RedCap Offering With Commercial Availability of RG255C-GL RedCap 5G Module

Embedded World--Quectel Wireless Solutions, a global IoT solutions provider, is delighted to announce the commercial availability of the RG255C-GL 5G RedCap Sub-6 GHz LGA module, delivering comprehensive 5G and 4G coverage across the globe. Based on Qualcomm Technologies, Inc.'s Snapdragon® X35 baseband chipset, the RG255C-GL offers exceptional wireless performance, empowering seamless low-latency 5G communication and advanced features including 5G LAN, URLLC, and network slicing.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240409408432/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Quectel broadens RedCap offering with commercial availability of RG255C-GL RedCap 5G module (Photo: Business Wire)

The RG255C-GL, conforming to 3GPP Release 17 standards, features a compact LGA form factor measuring 32.0mm x 29.0mm x 2.4mm. With impressive data rates of 223 Mbps downlink and 123 Mbps uplink, it is tailored for applications such as CPEs, MiFi, Router, Gateway, or Industrial PDA. Additionally, this module supports LTE Cat 4 and 5G Sub-6 SA mode, ensuring compatibility with Rel-15 and Rel-16 networks for seamless integration and versatile deployment.

Furthermore, the module is compatible with Quectel 4G module EG2x series modules with smaller sizes, which can meet customers’ different application demands for medium speed, large capacity, low latency, and high reliability, making it ideal for customers to design in to current device applications.

"Having the RG255C-GL 5G RedCap module commercially available offers our customers access to the benefits of 5G without the accompanying expense and power consumption," commented Norbert Muhrer, President and CSO, Quectel Wireless Solutions. "This technology paves the way for diverse IoT applications requiring worldwide 4G and 5G coverage with ultra-reliable low latency communications (URLLC) and network slicing."

RG255C-GL is designed for the global market and covers nearly all the mainstream carriers worldwide. The module features Qualcomm® IZat™️ location technology, offering GPS, GLONASS, BDS, and Galileo positioning functionalities. With its integrated GNSS receiver, customers can streamline their product design while enjoying enhanced positioning capabilities with greater speed and accuracy.

A wide range of interfaces including USB 2.0, PCle 2.0, PCM, UART, SGMII and SPI alongside a large number of drivers means that this module is ideal for a wide range of RedCap applications.

Quectel prioritizes security throughout the development of its IoT modules. Starting from product architecture to firmware/software development, Quectel integrates top industry practices and standards to address potential vulnerabilities. They collaborate with third-party independent test houses to mitigate risks and implement security measures such as generating SBOMs and VEX files, as well as conducting firmware binary analysis throughout the entire software development lifecycle.

The RG255C-GL RedCap module will be available alongside a series of antennas, providing developers with the ability to purchase module and antennas at the same time, reducing cost and time to market.

Attendees to Embedded World will be able to find out more about the RG255C-GL 5G RedCap module on the Quectel stand at booth number 3-318.

About Quectel

Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of 5,900 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules as well as antennas and services.

With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.

For more information, please visit: www.quectel.com, LinkedIn, Facebook, and X.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240409408432/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye